Fosravuconazole by Eisai for Tinea Pedis (Athlete Foot): Likelihood of Approval

Fosravuconazole is under clinical development by Eisai and currently in Phase II for Tinea Pedis (Athlete Foot).

ESC 2024: GLP-1RAs lower CV risk in meta-analysis of 32,883

Results have been presented at the European Society of Cardiology (ESC) Congress 2024 of a meta-analysis that studied the cardiovascular outcomes of glucagon-like peptide-1 receptor

September 2, 2024

atai Life Sciences Q1 2024 Earnings Report

The TDR Three Key Takeaways regarding atai Life Sciences Q1 2024 Earnings Report: atai Life Sciences reports a net loss of $26.7 million for Q1

May 16, 2024

No Effect of Tranexamic Acid on Bleeding in Surgery for Liver Cancer

Tranexamic acid (TXA) failed to reduce the need for red blood cell (RBC) transfusion following surgery for liver cancer, including colorectal liver metastases, the placebo-controlled

August 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.